NEM® open label human clinical trials

ESM Technologies’ NEM® brand eggshell membrane is a proven ingredient for the joint health market that delivers fast results. Two 30-day open label human clinical trials were conducted to evaluate NEM® (500mg once daily) for supporting joint and connective tissue.

Effect of NEM® on Joint Comfort

The results of the studies showed that supplementation with NEM® produced an average 25% improvement in joint comfort (both Study 1 & Study 2) in just 7 days. By the end of the 30-day trial, patients in Study 1 had an average improvement in comfort of more than 72%.  Patients in Study 2 experienced more moderate relief with an average 30% improvement in comfort at the completion of the trial, however about one-third of them experienced more than 50% improvement in comfort. No side effects were reported by study participants in either trial.

Effect of NEM® on Range of Motion

Supplementation with NEM® also produced an average 28% increase in flexibility in just 7 days for patients in Study 1. Flexibility had improved by an average 44% by the end of the study with more than half of the patients experiencing greater than 50% improvement in flexibility by day 30. NEM® not only improved joint flexibility, it also improved joint comfort in patients while flexing the affected joint in a range of motion (ROM) evaluation. At day 7, patients had 43% less discomfort while flexing, and by day 30, this had improved to 76% less discomfort while flexing. Again, no side effects were reported by study participants.

Supplementation with NEM® produced a significant treatment response at:

  • 7 days for flexibility (27.8% increase, P = 0.038)
  • 30 days for general discomfort (72.5% reduction, P = 0.007)
  • 30 days for flexibility (43.7% increase, P = 0.006)
  • 30 days for ROM-associated discomfort (75.9% reduction, P = 0.021)

Supplementation with NEM® produced a significant treatment response for discomfort at 7 days for both treatment arms.

(X: 18.4% reduction, P = 0.021,    Y: 31.3% reduction, P = 0.014)

There was no clinically meaningful difference between treatment arms at 7 days, so the Y arm crossed over to the X formulation for the remainder of the study.

The significant treatment response continued through 30 days for discomfort. (30.2% reduction,    P = 0.0001)


Clinical Interventions in Aging, (2009) 4:235-240.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Twitter Digg Delicious Stumbleupon Technorati Facebook Email